Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization

Viral Immunology

Volumn 22, Issue 2, 2009, Pages 125-130

  Chinchai, Teeraporn ^a   Chirathaworn, Chintana ^b   Praianantathavorn, Kesmanee ^b   Theamboonlers, Apiradee ^b   Hutagalung, Yanee ^c   Hans L , Bock P ^c   Thantiworasit, Pattarawat ^b   Poovorawan, Yong ^b  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B VACCINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; MALE; SEROLOGY; THAILAND; ADOLESCENT; BLOOD; IMMUNOASSAY; IMMUNOLOGY; SECRETION; T LYMPHOCYTE;

HEPATITIS B VIRUS;

ADOLESCENT; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOASSAY; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; T-LYMPHOCYTES; THAILAND; YOUNG ADULT;

EID: 65249109726     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0087     Document Type: Article

References (27)

1. Alberti A, Chemello L, and Benvegnu L: Natural history of hepatitis C. J Hepatol 1999;31:S17-S24.
2. Bauer T, and Jilg W: Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006;24: 572-577. (Pubitemid 43017822)
3. Chongsrisawat V, Yoocharoen P, Theamboonlers A, et al.: Hepatitis B seroprevalence in Thailand: twelve years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006; 11:1496-1502. (Pubitemid 44450554)
4. De Rosa SC, Lu FX, Yu J, et al.: Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004; 173:5372-5380. (Pubitemid 39392120)
5. European Consensus Group on Hepatitis B Immunity: Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-565.
6. Expanded programme on immunization. Global Advisory Group - Part II. Weekly Epidemiological Record 1991;66:9-12.
7. Ganem D, and Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129. (Pubitemid 38298992)
8. Huang CF, Lin SS, Ho YC, Chen FL, and Yang CC: The immune response induced by hepatitis B virus principal antigens. Cell Molec Immunol 2006;3:97-106.
9. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, and Chang MH: Long-term response ID hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999;29:954-959.
10. Kane M: Global programme for control of hepatitis B infection. Vaccine 1995;13:S47-S49.
11. Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, and Isikoglu B: The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine 2004;22:3963-3967. (Pubitemid 39208759)
12. Leclerc C, Sedlik C, Lo-Man R, Charlot B, Rojas M, and Deriaud E: Stimulation of a memory B cell response does not require primed helper T cells. Eur J Immunol 1995;25:2533-2538.
13. + T cells can be detected and characterized at the single cell level: limited usefulness of dendritic cells as single enhancers. J Immunological Methods 2008;330:1-11.
14. Lok AS, and McMahon BJ: Chronic hepatitis B. Hepatology 2001;34:1225-1241.
15. Lu CY, Ni YH, Chiang BL, et al.: Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008;197:1419-1426.
16. Manigold T, and Racanelli V: T-cell regulation by CD4 regulatory T cells during hepatitis B and C infections: facts and controversies. Lancet Infect Dis 2007;7:804-813. (Pubitemid 350152043)
17. Milich DR, and Leroux-Roels GG: Immunogenetics of the response to HBsAg vaccination. Autoimmunity Rev 2003; 2:248-257.
18. + T cells in human X-linked agammaglobulinemia. Blood 2002;99:2131-2137.
19. Poovorawan Y, Chongsrisawat V, Hutagalung Y, Srinavasa K, and Hoet B: Long-term efficacy of hepatitis B vaccination of newborns born of hepatitis B surface antigen-positive mothers in Thailand. J Clin Virol 2006;36(Suppl 2):S243-S244.
20. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, and Safary A: Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Fetal & Neonatal Arch Dis Child Fetal Neonatal 1997;77:F47-F51. (Pubitemid 28201628)
21. Poovorawan Y, Sanpavat S, Pongpunlert W, et al.: Comparison of the recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990;8:S56-S59. (Pubitemid 20154762)
22. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, and Safary A: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989;261:3278-3281. (Pubitemid 19143550)
23. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Vandepapeliere P, and Safary A: Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992;11:816-821.
24. Poovorawan Y, Theamboonlers A, Vimolket T, et al.: Persistence of antiHBs in children subjected to the EPI including HB vaccine in Thailand. Ann Trop Med Parasitol 2000; 94:615-621.
25. Sa-Nguanmoo P, Thongmee C, Ratanakorn P, et al.: Prevalence, whole genome characterization and phylogenetic analysis of hepatitis B virus in captive orangutan and gibbon. J Med Primatol 2008;37:277-289.
26. Wismans PJ, van Hattum J, de Gast GC, Bouter KP, Diepersloot RJ, Maikoe T, and Mudde GC: A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991;35:216-222.
27. Wismans PJ, van Hattum J, de Gast GC, et al.: The spot- ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin Exp Immunol 1989;78:75-79.